

S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. **Erythropoiesis-Stimulating Agents** [e.g. **erythropoietin (EPO)**, **darbepoetin (dEPO)**, **hypoxia-inducible factor (HIF) stabilizers**, **methoxy polyethylene glycol-epoetin beta (CERA)**, **peginesatide (Hematide)**];
2. **Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH)** and their releasing factors, in males;
3. **Corticotrophins** and their releasing factors;
4. **Growth Hormone (GH)** and its releasing factors and **Insulin-like Growth Factor-1 (IGF-1)**.

In addition, the following growth factors are prohibited

Fibroblast Growth Factors (FGFs), **Hepatocyte Growth Factor (HGF)**, **Mechano Growth Factors (MGFs)**, **Platelet-Derived Growth Factor (PDGF)**, **Vascular-Endothelial Growth Factor (VEGF)** as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching;

and other substances with similar chemical structure or similar biological effect(s).

S3. BETA-2 AGONISTS

All beta-2 agonists, including all optical isomers (e.g. *d*- and *l*-) where relevant, are prohibited except inhaled salbutamol (maximum 1600 micrograms over 24 hours), inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers' recommended therapeutic regimen.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an *Adverse Analytical Finding* unless the *Athlete* proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.